Key Points
- Major shareholder Ching Hang Shen bought 878,734 CapsoVision shares at an average price of $5.69, investing nearly $5 million and increasing their ownership by 42.91% to 2.93 million shares.
- CapsoVision reported a quarterly loss of $0.15 per share on $3.64 million in revenue, with a negative net margin of 214.74%; analysts expect a full-year loss of $0.56 per share.
- Analyst views are mixed, resulting in a consensus “Hold” rating and a $9.50 average price target, compared with the stock’s reported opening price of $6.70.
CapsoVision, Inc. (NASDAQ:CV - Get Free Report) major shareholder Ching Hang Shen purchased 878,734 shares of the business's stock in a transaction dated Tuesday, September 15th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $4,999,996.46. Following the completion of the acquisition, the insider owned 2,926,655 shares of the company's stock, valued at approximately $16,652,666.95. This represents a 42.91% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
CapsoVision Price Performance
CV stock opened at $6.70 on Friday. The stock has a market capitalization of $335.33 million, a P/E ratio of -14.26 and a beta of -2.47. CapsoVision, Inc. has a fifty-two week low of $4.34 and a fifty-two week high of $15.37. The business has a 50-day moving average of $6.41 and a 200-day moving average of $6.53.
CapsoVision (NASDAQ:CV - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $3.64 million during the quarter. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 177.85%. Equities analysts expect that CapsoVision, Inc. will post -0.56 EPS for the current year.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Zacks Research upgraded shares of CapsoVision to a "hold" rating in a report on Monday, August 31st. Benchmark reissued a "speculative buy" rating on shares of CapsoVision in a research report on Friday, August 14th. Roth Capital initiated coverage on CapsoVision in a research report on Friday, August 28th. They issued a "buy" rating and a $9.00 target price on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of CapsoVision in a research report on Monday, June 29th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $9.50.
Check Out Our Latest Research Report on CapsoVision
Hedge Funds Weigh In On CapsoVision
Several institutional investors and hedge funds have recently modified their holdings of CV. Connective Capital Management LLC bought a new position in shares of CapsoVision in the second quarter valued at about $76,000. Bank of America Corp DE bought a new stake in shares of CapsoVision during the 2nd quarter worth about $193,000. Legal & General Group Plc acquired a new position in CapsoVision in the 2nd quarter valued at about $26,000. BlackRock Inc. acquired a new position in CapsoVision in the 2nd quarter valued at about $14,372,000. Finally, Deutsche Bank AG bought a new position in CapsoVision in the 2nd quarter valued at about $263,000.
CapsoVision Company Profile
(
Get Free Report)
CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.
The company's principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
